Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

NCT00667082 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00667082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00667082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2008
Completion date
January 31, 2010
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, melanoma, multiple myeloma, non-small cell lung cancer, pancreatic cancer